Login to Your Account

Tysabri Developers Disclose Plan To Minimize Drug Risks

By Aaron Lorenzo

Wednesday, March 8, 2006
GAITHERSBURG, Md. - Biogen Idec Inc. unveiled details of its risk-management strategy for Tysabri (natalizumab), a proposed plan that generally received support from the FDA and multiple sclerosis patients, during the first day of a two-day public hearing on the once-heralded MS drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription